CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 9, 2012--
Verastem, Inc. (NASDAQ: VSTM), a biopharmaceutical company focused on
discovering and developing drugs to treat breast and other cancers by
targeting cancer stem cells, announced that the Company will be
presenting at the 2012 BD Biotech Conference on Tuesday, April 17 and
Wednesday April 18, 2012, at the Mandarin Oriental in Boston, MA.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to treat breast and other cancers by
targeting cancer stem cells. Cancer stem cells are an underlying cause
of tumor recurrence and metastasis. For more information please visit www.verastem.com.
Forward-looking statements:
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to
change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so.
Source: Verastem, Inc.
Investor contact:
Verastem, Inc.
Brian Sullivan,
617-252-9314
bsullivan@verastem.com
or
Media
contact:
For Verastem, Inc.
Kari Watson, 781-235-3060
kwatson@macbiocom.com
